These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 37223666)

  • 1. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial.
    Avezum Á; Oliveira Junior HA; Neves PDMM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Zimmermann SL; Silvestre OM; Seabra Prudente RC; Morales Kormann AP; Moreira FR; Boszczowski I; de Brito Sobrinho E; da Silva E Souza A; Seligman R; de Souza Paolino B; Razuk A; Diogenes de Magalhaes Feitosa A; Monteiro Belmonte PL; Freitas das Neves Gonçalves P; Hernandes ME; Fagundes AL; Sarmet Esteves JM; Tognon AP; Eikelboom J; Berwanger O; Lopes RD; Oliveira GBF;
    EClinicalMedicine; 2023 Jun; 60():102004. PubMed ID: 37223666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII).
    Oliveira GBF; Neves PDMM; Oliveira HA; Catarino DGM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Berwanger O; Lopes RD; Avezum Á
    Arq Bras Cardiol; 2023 Mar; 120(3):e20220431. PubMed ID: 37018790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
    Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
    Piazza G; Spyropoulos AC; Hsia J; Goldin M; Towner WJ; Go AS; Bull TM; Weng S; Lipardi C; Barnathan ES; Bonaca MP;
    Circulation; 2023 Jun; 147(25):1891-1901. PubMed ID: 37154020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
    Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
    Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
    Eikelboom JW; Jolly SS; Belley-Cote EP; Whitlock RP; Rangarajan S; Xu L; Heenan L; Bangdiwala SI; Luz Diaz M; Diaz R; Yusufali A; Kumar Sharma S; Tarhuni WM; Hassany M; Avezum A; Harper W; Wasserman S; Almas A; Drapkina O; Felix C; Lopes RD; Berwanger O; Lopez-Jaramillo P; Anand SS; Bosch J; Choudhri S; Farkouh ME; Loeb M; Yusuf S
    Lancet Respir Med; 2022 Dec; 10(12):1169-1177. PubMed ID: 36228641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial.
    Shah T; McCarthy M; Nasir I; Archer H; Ragheb E; Kluger J; Kashyap N; Paredes C; Patel P; Lu J; Kandel P; Song C; Khan M; Huang H; Ul Haq F; Ahmad R; Howes C; Cambi B; Lancaster G; Cleman M; Dela Cruz C; Parise H; Lansky A
    BMJ Open; 2023 Feb; 13(2):e067910. PubMed ID: 36828654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
    Cools F; Virdone S; Sawhney J; Lopes RD; Jacobson B; Arcelus JI; Hobbs FDR; Gibbs H; Himmelreich JCL; MacCallum P; Schellong S; Haas S; Turpie AGG; Ageno W; Rocha AT; Kayani G; Pieper K; Kakkar AK;
    Lancet Haematol; 2022 Aug; 9(8):e594-e604. PubMed ID: 35779560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.
    Avezum Á; Oliveira GBF; Oliveira H; Lucchetta RC; Pereira VFA; Dabarian AL; D O Vieira R; Silva DV; Kormann APM; Tognon AP; De Gasperi R; Hernandes ME; Feitosa ADM; Piscopo A; Souza AS; Miguel CH; Nogueira VO; Minelli C; Magalhães CC; Morejon KML; Bicudo LS; Souza GEC; Gomes MAM; Fo JJFR; Schwarzbold AV; Zilli A; Amazonas RB; Moreira FR; Alves LBO; Assis SRL; Neves PDMM; Matuoka JY; Boszczowski I; Catarino DGM; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Cavalcanti AB; Berwanger O;
    Lancet Reg Health Am; 2022 Jul; 11():100243. PubMed ID: 35378952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
    Perrotta C; Chahla J; Badariotti G; Ramos J
    Cochrane Database Syst Rev; 2020 May; 5(5):CD005259. PubMed ID: 32374919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
    Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P;
    Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.